HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Additive effects of exogenous IL-12 supplementation and antibiotic treatment in infection prophylaxis.

Abstract
The increasing clinical incidence and host risk of open fracture-associated infections, as well as the reduced effectiveness of conventional antibiotics to treat such infections, have driven the development of new therapies for the prophylaxis of open fracture-associated infections. We investigated percutaneous supplementation of a natural cytokine (i.e., interleukin 12p70 or IL-12) at an open fracture site to reduce open fracture-associated infections. We also determined the efficacy of the combination therapy of IL-12 and conventional antibiotic therapy in the prophylaxis of open fracture-associated infections. An open femur fracture infection model was produced by direct inoculation of a clinical isolate of Staphylococcus aureus after creating a femur fracture using rats. The animals were assigned to one of four groups: no drug administration, percutaneous supplementation of IL-12, intraperitoneal administration of the antibiotic ampicillin, or percutaneous IL-12 in combination with intraperitoneal ampicillin. Animals were euthanized at postoperative days 6, 10, 14, and 21. Percutaneous IL-12 led to a reduction in infection at postoperative days 6 and 10. For the first time, exogenous IL-12 was found to have additive effects in the prevention of infection when combined with conventional treatment (i.e., antibiotic therapy). Combination therapy of ampicillin and IL-12 substantially reduced the infection rate at postoperative day 6 and also decreased the time needed for complete inhibition of infection. Therefore, exogenous IL-12, providing a mechanism of protection independent of antibiotic resistance, complements the routine use of antibiotics.
AuthorsBrandon M Boyce, Brock A Lindsey, Nina B Clovis, E Suzanne Smith, Gerald R Hobbs, David F Hubbard, Sanford E Emery, John B Barnett, Bingyun Li
JournalJournal of orthopaedic research : official publication of the Orthopaedic Research Society (J Orthop Res) Vol. 30 Issue 2 Pg. 196-202 (Feb 2012) ISSN: 1554-527X [Electronic] United States
PMID21815205 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
CopyrightCopyright © 2011 Orthopaedic Research Society.
Chemical References
  • Interleukin-12
Topics
  • Animals
  • Antibiotic Prophylaxis
  • Bacterial Infections (prevention & control)
  • Drug Therapy, Combination
  • Fractures, Open (complications)
  • Interleukin-12 (administration & dosage)
  • Macrophage Activation
  • Rats
  • Rats, Sprague-Dawley
  • Weight Loss

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: